
The State Street Health Care Select Sector SPDR ETF (XLV) is designed to reflect, before expenses, the price and yield performance of the Health Care Select Sector Index. This benchmark offers a clear representation of the healthcare industry within the S&P 500. The fund provides focused exposure to companies across diverse healthcare fields, such as pharmaceuticals, medical equipment and supplies, healthcare providers and services, biotechnology, life sciences tools and services, and health technology. It allows investors to make targeted strategic or tactical allocations that are more precise than those offered by traditional style-based investment vehicles.
Is XLV's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.

Geopolitical shocks have pushed family offices to rethink nearly every corner of their portfolios. Infrastructure has emerged as the asset class they trust most right now.

FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.

The State Street Health Care Select Sector SPDR ETF might be a port in the storm for a while, but its best upside is likely behind it for this cycle. A year 2000-like cycle is hinting again. That's where XLV breaks even for a while, as tech melts down. But relative return is not a “win” to me. Any stock with a good chart is a potential trade for me. But as an investment, XLV and most of its component stocks are too richly valued.

State Street Investment Management is turning positive on healthcare stocks after nearly a year of caution. The firm's Q3 2026 sector outlook upgraded healthcare from neutral to positive.

JNJ's 25% year-to-date surge and recent FDA approval fuel interest in healthcare ETFs with diversified sector exposure.